213 related articles for article (PubMed ID: 21350803)
1. Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials.
Shitara K; Ikeda J; Yokota T; Takahari D; Ura T; Muro K; Matsuo K
Invest New Drugs; 2012 Jun; 30(3):1224-31. PubMed ID: 21350803
[TBL] [Abstract][Full Text] [Related]
2. Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer.
Shitara K; Matsuo K; Muro K; Doi T; Ohtsu A
Gastric Cancer; 2014 Apr; 17(2):362-70. PubMed ID: 23736742
[TBL] [Abstract][Full Text] [Related]
3. Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials.
Li L; Pan Z
Clin Breast Cancer; 2018 Feb; 18(1):63-70. PubMed ID: 28818493
[TBL] [Abstract][Full Text] [Related]
4. Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials.
Petrelli F; Barni S
Med Oncol; 2014 Jan; 31(1):776. PubMed ID: 24271313
[TBL] [Abstract][Full Text] [Related]
5. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
Tang PA; Bentzen SM; Chen EX; Siu LL
J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
[TBL] [Abstract][Full Text] [Related]
6. Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy.
Shitara K; Matsuo K; Muro K; Doi T; Ohtsu A
J Cancer Res Clin Oncol; 2013 Aug; 139(8):1383-9. PubMed ID: 23708301
[TBL] [Abstract][Full Text] [Related]
7. Correlation between overall survival and other endpoints in metastatic breast cancer with second- or third-line chemotherapy: Literature-based analysis of 24 randomized trials.
Liu L; Chen F; Zhao J; Yu H
Bull Cancer; 2016 Apr; 103(4):336-44. PubMed ID: 26874974
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
Burzykowski T; Buyse M; Piccart-Gebhart MJ; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
J Clin Oncol; 2008 Apr; 26(12):1987-92. PubMed ID: 18421050
[TBL] [Abstract][Full Text] [Related]
9. Association Between Intermediate End Points, Progression-free Survival, and Overall Survival in First-line Advanced or Recurrent Endometrial Cancer.
Garside J; Shen Q; Westermayer B; van de Ven M; Kroep S; Chirikov V; Juhasz-Böss I
Clin Ther; 2023 Oct; 45(10):983-990. PubMed ID: 37689551
[TBL] [Abstract][Full Text] [Related]
10. Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer.
Ciani O; Buyse M; Garside R; Peters J; Saad ED; Stein K; Taylor RS
J Clin Epidemiol; 2015 Jul; 68(7):833-42. PubMed ID: 25863582
[TBL] [Abstract][Full Text] [Related]
11. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer.
Hamada T; Nakai Y; Isayama H; Yasunaga H; Matsui H; Takahara N; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Tada M; Koike K
Eur J Cancer; 2016 Sep; 65():11-20. PubMed ID: 27451020
[TBL] [Abstract][Full Text] [Related]
12. Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer.
Forsythe A; Chandiwana D; Barth J; Thabane M; Baeck J; Tremblay G
Breast Cancer (Dove Med Press); 2018; 10():69-78. PubMed ID: 29765247
[TBL] [Abstract][Full Text] [Related]
13. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
Michiels S; Pugliano L; Marguet S; Grun D; Barinoff J; Cameron D; Cobleigh M; Di Leo A; Johnston S; Gasparini G; Kaufman B; Marty M; Nekljudova V; Paluch-Shimon S; Penault-Llorca F; Slamon D; Vogel C; von Minckwitz G; Buyse M; Piccart M
Ann Oncol; 2016 Jun; 27(6):1029-1034. PubMed ID: 26961151
[TBL] [Abstract][Full Text] [Related]
14. TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials.
Lee DW; Jang MJ; Lee KH; Cho EJ; Lee JH; Yu SJ; Kim YJ; Yoon JH; Kim TY; Han SW; Oh DY; Im SA; Kim TY
Br J Cancer; 2016 Nov; 115(10):1201-1205. PubMed ID: 27736843
[TBL] [Abstract][Full Text] [Related]
15. Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization?
Celsa C; Cabibbo G; Enea M; Battaglia S; Rizzo GEM; Busacca A; Giuffrida P; Stornello C; Brancatelli G; Cannella R; Gruttadauria S; Cammà C
Liver Int; 2021 May; 41(5):1105-1116. PubMed ID: 33587814
[TBL] [Abstract][Full Text] [Related]
16. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
[TBL] [Abstract][Full Text] [Related]
17. Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma.
Delea TE; Khuu A; Heng DY; Haas T; Soulières D
Br J Cancer; 2012 Sep; 107(7):1059-68. PubMed ID: 22935581
[TBL] [Abstract][Full Text] [Related]
18. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
Zhao S; Zhang Z; Zhang Y; Hong S; Zhou T; Yang Y; Fang W; Zhao H; Zhang L
Int J Cancer; 2019 Jun; 144(11):2854-2866. PubMed ID: 30430561
[TBL] [Abstract][Full Text] [Related]
19. Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis.
Beauchemin C; Johnston JB; Lapierre MÈ; Aissa F; Lachaine J
Curr Oncol; 2015 Jun; 22(3):e148-56. PubMed ID: 26089725
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]